Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Contraception Age: Adult |
Dose: Tablet – 1 active tablet Frequency: once daily Duration: 24 days, then 1 inert tablet (levomefolate calcium) once daily for 4 days |
|
Indication: Premenstrual Dysphoric Disorder (PMDD) Age: Adult Condition: Symptoms of Premenstrual Dysphoric Disorder, but only if oral contraceptive is chosen as method of birth control |
Dose: Tablet – 1 active tablet Frequency: once daily Duration: 24 days, then 1 inert tablet (levomefolate calcium) once daily for 4 days |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Contraception Age: 14 years and older (post-menarchal) |
Dose: Tablet – 1 tablet (consisting of 3 mg drospirenone, 0.02 mg or 0.03 mg ethinyl estradiol, and 0.451 mg levomefolate calcium for 21-24 days, followed by 4-7 days of levomefolate calcium only) Frequency: once daily Note: by mouth (oral) |
|
Indication: Moderate acne vulgaris Age: 14 years and older (post-menarchal) |
Dose: Tablet – 1 tablet (consisting of 3 mg drospirenone, 0.02 mg or 0.03 mg ethinyl estradiol, and 0.451 mg levomefolate calcium for 21-24 days, followed by 4-7 days of levomefolate calcium only) Frequency: once daily Note: by mouth (oral) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Tablet – Fixed dose Note: Renal impairment: Contraindicated |
Administration
- Take one orange tablet daily for 21 days
- Then take one light orange tablet daily for 7 days
Side Effect
- Hypertension
- Hypersensitivity
- Hyperkalemia
- Chloasma
- Gallbladder disease
- Toxic skin eruption
- Uterine leiomyoma
- Premenstrual syndrome (13.2%)
- Migraine/headache (10.7%)
- Breast pain/discomfort/tenderness (8.3%)
- Menstrual irregularities (4.7%)
- Nausea/vomiting (4.5%)
- Abdominal pain/discomfort/tenderness (2.3%)
- affect lability
- depression
- alteration of mood
- mood swings
- and irritability (2.3%)
- Irregular uterine bleeding
- DVT
- PE
- stroke
- MI
- intracardiac thrombosis
- sagittal sinus thrombosis
- intracranial venous sinus thrombosis
- retinal vein thrombosis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 inducers
|
May decrease effectiveness of COCs or increase breakthrough bleeding
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Renal impairment
|
Can cause fluid retention and electrolyte imbalance
|
|
Arterial/venous thrombosis risk
|
Can increase risk of blood clots
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.